Italy · Delayed Price · Currency is EUR EL.En. Earnings Call Transcripts
Fiscal Year 2026
-
H1 2026 saw over 9% revenue growth, driven by the medical segment, now 92% of revenues after the laser cutting divestiture. Profitability improved sharply, with EBITDA margin at 19.8% and net result up 45%. Guidance for 2026 is confirmed, with strong H2 expected and continued focus on organic growth and selective M&A.
-
Q1 2026 saw 3.3% revenue growth to EUR 145.6 million, led by strong medical sector performance and improved margins, while industrial sales declined but profitability improved. Guidance for 2026 is confirmed, targeting 5% revenue growth and higher EBIT margin, with both segments expected to contribute.
Fiscal Year 2025
-
FY2025 saw 4.4% revenue growth and strong medical sector performance, but net profit declined due to higher provisions, FX losses, and one-time items. Guidance for 2026 is cautious, targeting 5% revenue growth amid geopolitical and supply chain uncertainties.
-
Strong Q3 driven by medical sector growth and high-margin products, with consolidated revenue up 3.9% and gross margin improving. Industrial segment faced delays and competition, but cash position strengthened by asset sales. Confident in meeting 2024 guidance.
-
Revenue grew 5% YoY to €285M, led by medical sector gains, while EBIT and net income declined due to weaker industrial performance, FX losses, and non-recurring items. Guidance for revenue growth is reaffirmed, with a strong order backlog supporting confidence despite ongoing macroeconomic and competitive pressures.
-
Revenue grew 8.8% year-over-year to EUR 140.9 million, with both medical and industrial sectors contributing. EBIT and margins improved, and 2025 guidance was raised, expecting to beat 2024 revenue and EBIT. U.S. tariffs and global uncertainties remain key risks.
-
A majority stake in Penta Laser Zhejiang was sold to YOFC for EUR 30.5 million, with Italian operations retained to preserve market confidence. 2025 guidance targets revenue growth and stable EBIT, with medical and industrial sectors both expected to improve despite margin pressures.
Fiscal Year 2024
-
2024 saw medical segment growth and industrial decline, with strong margins and net income up 7%. Guidance for 2025 is cautious due to global uncertainties, legal risks, and expected revenue loss from key clients, but financial solidity and internal investment remain priorities.
-
Q3 2024 saw a recovery in profitability, with EBIT nearly matching 2023 levels despite a 5.4% revenue decline year-over-year. The medical sector grew, offsetting industrial weakness, and the planned sale of the laser cutting business will shift future focus and reporting.
-
A preliminary agreement was signed to sell majority stakes in the laser cutting division to YOFC for EUR 55.3 million, with closing expected in early 2025. The deal will significantly improve the net financial position and allow a strategic focus on the medical business, with future M&A possible but not yet planned.
-
H1 2024 saw revenues decline 9% year-over-year, mainly due to industrial sector weakness, but EBIT margin remained strong and net income rose on a one-time gain. Medical sector resilience and a favorable sales mix support guidance for higher full-year EBIT despite lower revenues.